Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BJ-005 in Advanced Solid Tumor or Lymphoma
NCT05115292Phase 1Active, not recruiting
- Sponsor
- BJ Bioscience Inc.
- Start
- Oct 2021
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial of BJ-005 in solid tumor (advanced stage) and lymphoma (2 arms), sponsored by BJ Bioscience Inc. Primary endpoints: Incidence and frequency of adverse events, Maximum Tolerated Dose and/or Recommended Phase 2 Dose and 1 more. Started Oct 2021; status: active, not recruiting.
02
Drugs
BJ-005
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT05115292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05115292.